You just read:

Rich Pharmaceuticals Further Extends CRO Agreement with Theradex Systems To Manage Upcoming Phase 1/2 Clinical Trial for its Acute Myelocytic Leukemia (AML) and Myelodysplastic Syndrome (MDS) Drug in the United States

News provided by

Rich Pharmaceuticals, Inc.

30 Mar, 2016, 09:45 ET